About Excelra
Excelra is a company based in Hyderabad (India) founded in 2001. Excelra has raised $163.84 thousand across 1 funding round from investors including Destiny Investments. The company has 622 employees as of April 01, 2024. Excelra has completed 1 acquisition, including BISC Global. Excelra offers products and services including GOSTAR™ Small Molecules, BioVisualizer™, and Online Pipeline Platform (OP²)®. Excelra operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Hyderabad, India
- Employees 622 as on 01 Apr, 2024
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Excelra Knowledge Solutions Private Limited
- Date of Incorporation 24 Feb, 2006
- Jurisdiction Hyderabad, Telangana, India
-
Annual Revenue
$34.4 M (USD)0as on Mar 31, 2023
-
Net Profit
$7.42 M (USD)0as on Mar 31, 2023
-
EBITDA
$10.57 M (USD)0as on Mar 31, 2023
-
Total Equity Funding
$163.84 K (USD)
in 1 rounds
-
Latest Funding Round
$163.84 K (USD), Seed
Jul 29, 2016
- Investors
-
Employee Count
622
as on Apr 01, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Excelra
Excelra offers a comprehensive portfolio of products and services, including GOSTAR™ Small Molecules, BioVisualizer™, and Online Pipeline Platform (OP²)®.
SAR database for small molecule drug discovery and analysis
Platform for visualizing and analyzing biomedical data
No-code tool for sequencing data processing and insights
People of Excelra
Unlock access to complete
Funding Insights of Excelra
Excelra has successfully raised a total of $163.84K through 1 strategic funding round. The most recent funding activity was a Seed round of $163.84 thousand completed in July 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $163,836
-
First Round
First Round
(29 Jul 2016)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2016 | Amount | Seed - Excelra | Valuation | Destiny Investments |
|
Investors in Excelra
Excelra has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Destiny Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides comprehensive investment advisory services to help clients achieve financial goals.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Excelra
Excelra has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include BISC Global.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bioinformatics and biostatistics services are provided to life science firms.
|
2017 |
Financial Statements - Excelra
Excelra Comparisons
Competitors of Excelra
Excelra operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Latest news on Excelra
Frequently Asked Questions about Excelra
Excelra was founded in 2001 and raised its 1st funding round 15 years after it was founded.
Excelra is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
Anandbir Singh Brar is the current CEO of Excelra.
Excelra is a funded company, having raised a total of $163.84K across 1 funding round to date. The company's 1st funding round was a Seed of $163.84K, raised on Jul 29, 2016.
As of Apr 01, 2024, the latest employee count at Excelra is 622.
Annual revenue of Excelra is $34.4M as on Mar 31, 2023.
Excelra develops a bioinformatics platform for the in silico analysis of drug candidate. The companys product GOSTAR is a SAR database that provides information on SAR, ADME, toxicity, preclinical, clinical, and structural data, GOBIOM is a repository of biomarkers reported in pre-clinical, clinical and exploratory phases, CTOD is a Clinical Trial Outcome Database. The company also develops and markets a suite of clinical trial outcomes databases. It also develops clinical databases that support MBMA on a custom basis. It also offers services for drug and biomarker discovery. It was previously known as GVK Informatics.
Excelra's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Excelra offers GOSTAR™ Small Molecules, BioVisualizer™, and Online Pipeline Platform (OP²)®.
Excelra has made 1 acquisition, including BISC Global.
Excelra has 1 investor. Key investors include Destiny Investments.